France and Germany Recall Diabetes Drug Actos Due to Increased Risk of Bladder Cancer
On June 9, 2011, French health authorities recalled Actos (Pioglitazone) after recent research inferred that side effects of Actos may include an increased risk of bladder cancer. France’s Medical Regulatory Agency’s decision to remove Actos from the market came after an evaluation of French public insurance data found that the side effects of Actos are linked to a minor increase in the risk of bladder cancer. In France, Actos is taken by roughly 230,000 people. Similarly, on June 10, 2011, Germany followed suit when the country’s health regulators advised physicians to stop prescribing the Type 2 diabetes drug because of the severe and dangerous side effects of Actos. This action was prompted after the European Medicines Agency conducted its own study of pioglitazone-containing medicines. The study results suggested that the side effects of Actos could increase the risk of bladder cancer. German health regulators released a statement, recommending “the suspension of approval of pioglitazone until further clarification. Doctors should not put new patients on pioglitazone.” The announcement from Germany’s Federal Institute for Drugs and Medical Devices follows France’s decision to halt the use of drugs containing pioglitiazone because of the dangerous side effects of Actos.
Actos, or pioglitazone, is an oral diabetes medication that was approved by the Food and Drug Administration (“FDA”) in July 1999 as a treatment for Type 2 diabetes. Actos is part of the same class of drugs as Avandia, which has also been linked to an increased risk of myocardial infarctions (heart attacks) and other serious health problems, similar to the side effects of Actos.
Side Effects of Actos (Pioglitazone) Linked to Bladder Cancer
In September 2010, the FDA announced that it was investigating the possible link between bladder cancer and the Type 2 diabetes drug Actos after early numbers from a continuous 10 year study regarding the side effects of Actos. The study, which was conducted by Takeda Pharmaceuticals, the drug’s manufacturer, suggested that users of the drug may face an increased risk of bladder cancer the longer the drug is taken, increasing the potential risk that users will suffer side effects of Actos. In May 2011, a new study was published by the FDA, which provided more evidence that suggested that one of the side effects of Actos is an increase in the risk of bladder cancer. Researchers looking at the published report found that about one-fifth of all reports involving bladder cancer among diabetes drug users involved Actos pioglitazone. Researchers have suggested that there may be a disparate risk in comparison to other Type 2 diabetes drugs. An analysis of data recently published in the journal, Diabetes Care found a 40 percent increased risk of bladder cancer in patients who took Actos for at least two years.
If you or a loved one has experienced any side effects of Actos, , such as bladder cancer, you may be able to file a lawsuit seeking compensation for your medical expenses, pain and suffering, lost wages and more. Contact one of our Actos lawyers today for a free and confidential lawsuit evaluation. The lawyers at Bernstein Liebhard LLP have extensive litigation experience and have recovered billions of dollars for their clients. In addition to being staunch advocates for your claim, our Actos injury lawyers also provide personal attention to guide you through the complex litigation process.